The human bioreactor: Projecting clinical efficacy for an mRNA-encoded HIV-1 antibody
Lipid nanoparticles (LNPs) are the most clinically advanced and efficient method for delivering messenger RNA (mRNA), with most studies focusing on cancer mRNA vaccines and prophylactic mRNA vaccines against infectious diseases.1 Recent developments in this field have prompted researchers to explore the applicability of this platform toward additional therapies, such as mRNA-encoded antibody therapy.2 Unlike conventional recombinant antibody therapy, which is considered time-consuming and labor intensive, mRNA-encoded antibody therapy is faster, simpler, and more scalable.
Authors
- Uri Elia (ORCID: https://orcid.org/0000-0003-0710-5481)
- Ofer Cohen (ORCID: https://orcid.org/0000-0002-4374-9981)
Institutions
- Israel Institute for Biological Research (IL)
Publication Details
- Journal
- Molecular Therapy — Nucleic Acids
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1016/j.omtn.2026.103164
- Primary Topic
- RNA Interference and Gene Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00